Citations

Clear

6274 citation(s) found for "To, Andrew".

Blood-Labyrinthine Barrier Permeability Assessed Using Postcontrast Delayed 3D-FLAIR MRI Imaging in Vestibular Schwannoma
Carlson, Michael Luke , Lane, John I. , Bowen, Andrew J. , Carlson, Michael L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 5, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0040-1702404 Get It

Performance Characteristics of a Multiplex Flow Immunoassay for Detection of IgG-Class Antibodies to Measles, Mumps, Rubella, and Varicella-Zoster Viruses in Presumptively Immune Health Care Workers
Theel, Elitza S. , Sorenson, Marisa, Rahman, Crystal, Granger, Dane, Vaughn, Andrew I. S., Breeher, Laura E. , Vaughn, Andrew, Breeher, Laura, Breeher, Laura

Mayo Clinic

Journal of Clinical Microbiology | February 5, 2020 | Volume: 58 | Issue: 4 | Pages: No page available

10.1128/jcm.00136-20 | PMID 32024728 Get It

Immunity to measles, mumps, rubella, and varicella-zoster viruses (VZV; MMRV) is a common condition of employment for health care workers (HCWs) to ensure compliance with national standards and state laws. When documentation of complete vaccination or laboratory-confirmed infection is not available, Advisory Committee on Immunization Practices (ACIP) criteria are used to guide vaccination or anti-MMRV IgG testing. We assessed the performance of the BioPlex 2200 MMRV IgG multiplex flow immunoassay (MFI; Bio-Rad Laboratories, Hercules, CA) and matched immunofluorescence assays (IFAs; MBL Bion, Des Plaines, IL) in 220 HCWs categorized by ACIP criteria for presumptive immunity to MMRV.
A Case of Linear Cutaneous Lupus Erythematosus in a 55-Year-Old Woman
Milosavljevic, Katarina, Fibeger, Emily, Virata, Andrew, Virata, Andrew R

Mayo Clinic

American Journal of Case Reports | February 5, 2020 | Volume: 21 | Issue: No issue available | Pages: No page available

10.12659/ajcr.921495 | PMID 32173718 Get It

Improving cascade genetic testing for families with inherited pancreatic cancer (PDAC) risk: The GENetic Education, Risk Assessment and TEsting (GENERATE) study.
Yurgelun, Matthew B. , Furniss, C. Sloane , Kenner, Barbara , Lowy, Andrew M. , McAllister, Florencia , Mork, Maureen E. , Nelson, Scott H., Robertson, Alison, Stopfer, Jill E. , Ocean, Allyson J. , Madlensky, Lisa , Petersen, Gloria M. , Lippman, Scott M. , Ukaegbu, Chinedu I. , Klein, Alison P. , Nelson, Scott H., Underhill‐Blazey, Meghan , Garber, Judy E. , Goggins, Michael , Maitra, Anirban , Syngal, Sapna

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: TPS779-TPS779

10.1200/jco.2020.38.4_suppl.tps779 Get It

TPS779 Background: 4-10% of PDAC patients harbor pathogenic germline variants in cancer susceptibility genes, including APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, and TP53. For families with such pathogenic variants, the greatest potential impact of germline testing is to identify relatives with the same variant (cascade testing), thereby providing the opportunity for early detection and interception of PDAC and other associated cancers. Numerous factors limit cascade testing in real-world practice, including family dynamics, widespread geographic distribution of relatives, access to genetic services, and misconceptions about the importance of germline testing, such that the preventive benefits of cascade testing are often not fully realized. The primary aim of this study is to analyze two alternative strategies for cascade testing in families with inherited PDAC risk. Methods: 1000 individuals with a confirmed pathogenic germline variant in any of the above genes in a 1st/2nd degree relative and a 1st/2nd degree relative with PDAC will be remotely enrolled through the study website (www.GENERATEstudy.org) and randomized between two methods of cascade testing (individuals with prior genetic testing will be ineligible): Arm 1 will undergo pre-test genetic education with a pre-recorded video and live interactive session with a genetic counselor via a web-based telemedicine platform (Doxy.me), followed by germline testing through Color Genomics; Arm 2 will undergo germline testing through Color Genomics without dedicated pre-test genetic education. Color Genomics will disclose results to study personnel and directly to participants in both arms. All participants will have the option of pursuing additional telephone-based genetic counseling through Color Genomics. The primary outcome will be uptake of cascade testing. Secondary outcomes will include self-reported genetic knowledge, cancer worry, distress, decisional preparedness, familial communication, and screening uptake, which will be measured via longitudinal surveys. Enrollment is underway nationwide as of May, 2019. Clinical trial information: NCT03762590.
Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers.
Ko, Andrew H. , Wolpin, Brian M. , Clark, Jeffrey W. , Cheng, Yi‐Lin, Cheng, Ting-Ying, Langecker, P., Coveler, Andrew L. , Schlechter, Benjamin L. , Bekaii‐Saab, Tanios , Lin, Shih-Yao

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: 713-713

10.1200/jco.2020.38.4_suppl.713 Get It

713 Background: AbGn-107 is an ADC directed against AG-7 antigen, a Lewis A-like glycol-epitope expressed in 24-61% of gastric (G), colorectal (CRC), pancreatic (PDA), and biliary (BIL) cancers. Based on promising antitumor activity of AbGn-107 in both in vitro and in vivo preclinical studies, we performed a Phase Ia trial in pts with the aforementioned GI malignancies. Methods: Standard 3+3 dose escalation was used. Key eligibility criteria: locally adv or metastatic G, CRC, PDA, or BIL cancer, previously treated, ECOG PS 0-1; positive AG-7 expression was not required. Two dosing intervals were tested: AbGn-107 administered i.v. Q4 weeks (at doses ranging from 0.1-1.2 mg/kg) and Q2 weeks (at doses from 0.8-1.0 mg/kg). DLTs were based on grade 3/4 hematologic and non-heme AEs occurring during the initial 4-week rx window. Pts were treated until dz progression or unacceptable toxicity, with tumor assessments Q8 weeks. 1o objectives: safety and MTD; 2o objectives: PK, immunogenicity, and efficacy defined by ORR (RECIST 1.1). Results: 35 patients were enrolled across 6 dose levels (median age 61.5 yo (range 40 – 81); G (0)/CRC (12)/PDA (20)/BIL (3); median # lines of prior rx = 3 (range 1-7). Safety: 5 pts experienced Grade 3 or 4 neutropenia, all at higher dose levels, with 1 episode of febrile neutropenia. Other frequent drug-related AEs, mostly grade 1/2, inc. fatigue (29%), nausea (20%), and diarrhea (14%). DLTs include grade 4 CK elevation (n = 1) at 0.8 mg/kg Q4W and grade 3 arthralgias (n = 1) at 1.2 mg/kg Q4W. MTD was not reached at either 1.2 mg/kg Q4W or 0.8 mg/kg Q2W; the 1.0 mg/kg Q2W cohort will complete enrollment in Oct 2019. Efficacy: Median duration of treatment = 56 days (range, 8 – 225 days); best response observed to date is stable dz lasting > 6 months at 0.8 mg/kg Q4W and Q2W cohorts (n = 1 each). Conclusions: Overall, AbGn-107 appears well-tolerated with encouraging prelim signs of efficacy (prolonged dz control) in non-biomarker selected pts with advanced GI cancers. Pre-screening for high AG-7 expression is underway for subjects with G, CRC, PDA, and BIL cancers for the cohort expansion phase of this study, which will be open across multiple sites in U.S. and Taiwan. Clinical trial information: NCT02908451.
Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma.
Pappas, Leon, Reyes, Stephanie , Lanka, Aishwarya, Shroff, Rachna T. , Rahma, Osama E. , Bocobo, Andrea Grace, DeLeon, Thomas, Mody, Kabir , Roth, Marc, Goff, Laura W. , Boyhen, Kylie, VanCott, Christine, Zhu, Andrew X. , Javle, Milind , Kelley, Robin Kate , Le, Tri Minh , Borad, Mitesh J. , Roth, Marc Thomas, Peters, Mary Linton B , Horick, Nora , Goyal, Lipika

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: 580-580

10.1200/jco.2020.38.4_suppl.580 Get It

580 Background: Though studies indicate that the genomic profiles of ICC and ECC are distinct, the clinical features that differentiate them still remain to be well characterized. The purpose of this study was to further analyze these differences and patient treatment patterns in a multi-center cohort. Methods: A retrospective chart review was performed at 8 institutions on patients (pts) with ICC or ECC diagnosed after June 2009. Data on demographics, risk factors, treatments, pathology and overall survival (OS) were collected. Tumor genotyping results from CLIA-certified tissue assays were analyzed. Fisher’s exact, Wilcoxon rank sum and log-rank tests were used to compare sub-groups. Results: In a database of 737 pts with cholangiocarcinoma, 538(73%) had ICC and 199(27%) had ECC. Pts with ICC more often presented in later stages, had tumors > 5cm at resection (p < 0.0001) and had metastases to the liver, lymph nodes, lung and/or bone (p < 0.01). Pts with ICC more often received liver directed therapy, targeted therapy and multiple lines of systemic therapy and they more often enrolled in a clinical trial (all p < 0.01). Pts with ECC were more likely to be male, undergo surgery, receive adjuvant chemotherapy and/or chemoradiation (all p < 0.05). Mutation profiling performed in 381 (52%) pts (ICC/ECC = 301/80) showed that pts with ICC were more likely to have IDH1 mutations and FGFR2 fusions, whereas pts with ECC were more likely to have KRAS, APC, SMAD4, WNT, TGFb and TP53 mutations (all < 0.05). Factors that did not differ significantly between pts with ICC and ECC include race, rates of primary sclerosing cholangitis, median diagnosis CA19-9 levels and R1 resection rate. Median OS from diagnosis was 18.9 months in ICC and 17.3 months in ECC (p = 0.8471). Conclusions: While pts with ICC and ECC have some similarities in their clinical features, differences in metastases patterns and molecular profiling significantly impact their management such that pts with ICC receive more liver-directed therapy, targeted therapy and more lines of systemic therapy. Further prospective studies are needed as referral patterns to tertiary care centers may have impacted these results.
Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms
Duncombe, Andrew , Anderson, Lesley , James, Glen , Vocht, Frank de , Mesa, Ruben, Anderson, Lesley A , Fritschi, Lin , Mesa, Ruben A. , Clarke, Mike J , McMullin, Mary Frances

Mayo Clinic

HemaSphere | February 3, 2020 | Volume: 4 | Issue: 1 | Pages: No page available

10.1097/hs9.0000000000000327 | PMID 32072143 Get It

AbstractDespite the identification of acquired genetic mutations associated with Myeloproliferative Neoplasms (MPNs) there is a paucity of information relating to modifiable risk factors that may lead to these mutations. The MOSAICC Study was an exploratory case‐control study of polycythemia vera (PV), essential thrombocythemia (ET), and Myelofibrosis (MF). MPN patients and population controls (identified by General Practitioners) and non‐blood relative/friend controls were recruited from 2 large UK centers. Participants completed a telephone‐based questionnaire analyzed by unconditional logistic regression analysis adjusting for potential confounders. Risk factors for MPNs identified included increasing childhood household density [odds ratio (OR) 2.55, 95% confidence interval (CI) 1.16–5.62], low childhood socioeconomic status (OR 2.30, 95%CI 1.02–5.18) and high pack years smoking (OR 2.19, 95%CI 1.03–4.66) and current smoking restricted to JAK2 positive PV cases (OR 3.73, 95%CI 1.06–13.15). Obesity was linked with ET (OR 2.59, 95%CI 1.02–6.58) confirming results in previous cohort studies. Receipt of multiple CT scans was associated with a strongly increased risk of MPN although with wide confidence intervals (OR 5.38, 95%CI 1.67–17.3). Alcohol intake was inversely associated with risk of PV (OR 0.41, 95%CI 0.19–0.92) and ET (OR 0.48, 95%CI 0.24–0.98). The associations with childhood household density, high pack years smoking and alcohol were also seen in multivariate analysis. This is the largest case control study in MPNs to date and confirms the previously reported associations with obesity and cigarette smoking from cohort studies in addition to novel associations. In particular, the role of smoking and JAK2 mutation cases merits further evaluation.
Implications for medication dosing for transgender patients: A review of the literature and recommendations for pharmacists
Webb, Andrew , McManus, Dayna , Rouse, Ginger, Vonderheyde, Robyn, Topal, Jeffrey , Webb, Andrew J

Mayo Clinic

American Journal of Health-System Pharmacy | February 3, 2020 | Volume: 77 | Issue: 6 | Pages: 427-433

10.1093/ajhp/zxz355 | PMID 32012216 Get It

Abstract Purpose Transgender patients face considerable healthcare disparities. Improved means of recognizing transgender patients and understanding their medical needs is important to provide optimal care. The electronic medical record (EMR) of our health system allows for differentiation of gender identity, legal sex, and sex at birth. With EMR recognition of transgender patients, a recommendation for estimating creatinine clearance (CLcr) and ideal body weight (IBW) was needed to standardize medication dosing. Summary The literature was reviewed for evidence on the effect of gender-affirming hormone therapy on serum creatinine concentration and lean body mass. Findings informed a recommendation for drug dosing based on CLcr and IBW in transgender patients. Four studies that reported the effect of hormone therapy on biometric laboratory values were found. Three studies reported that values of transgender patients more closely resembled the standard values of their gender identity vs sex at birth after hormone therapy; 1 study reported a range of values that more closely resembled those associated with sex at birth while still overlapping with values associated with gender identity. Consequently, it was recommended that pharmacists dose medications based on CLcr and IBW calculations consistent with gender identity after a patient has been on hormone therapy for 6 months or longer. Conclusion Providing optimal care to transgender patients includes considering the effect of gender-affirming hormone therapy on overall physiology. Consistently using the appropriate CLcr and IBW calculations for each patient ensures safe and effective care. Additional studies are needed to confirm the effect of hormone therapy on renal clearance and lean body mass.
Mesenteric panniculitis in a patient with new onset dermatomyositis
Bansal, Pankaj , Gilbert, Emily, Pereira, Rodrigo Otavio Lami , Virata, Andrew, Gilbert, Emily L , Virata, Andrew R, Bansal, Pankaj

Mayo Clinic

BMJ Case Reports | February 3, 2020 | Volume: 13 | Issue: 1 | Pages: e232183

10.1136/bcr-2019-232183 | PMID 32014990 Get It

Mesenteric panniculitis (MP), part of the spectrum of sclerosing mesenteritis, is an often asymptomatic disorder that is characterised by chronic inflammation of abdominal mesentery. We present a case of an 83-year-old woman who presented with proximal muscle weakness and erythematous, photosensitive rash of the face and upper torso and was subsequently diagnosed with dermatomyositis based on skin biopsy, electromyography and muscle biopsy. She had radiographic evidence of panniculitis on CT scan of the abdomen and pelvis for malignancy surveillance, which improved on serial CT scan 3 months after beginning treatment for her underlying dermatomyositis with prednisone and mycophenolate mofetil. Our case highlights that MP can be associated with underlying autoimmune disease. Connective tissue disease could be considered in the differential of MP when other etiologies such as surgery, trauma and malignancy are ruled out.
The Effects of Cholecalciferol Supplementation on Vitamin D Status Among a Diverse Population of Collegiate Basketball Athletes: A Quasi-Experimental Trial
Sekel, Nicole M. , Gallo, Sina , Fields, Jennifer B. , Jagim, Andrew R. , Wagner, Tammy L., Jones, Margaret T. , Jagim, Andrew R

Mayo Clinic

Nutrients | January 31, 2020 | Volume: 12 | Issue: 2 | Pages: 370

10.3390/nu12020370 | PMID 32023809 Get It

Vitamin D may play a role in performance and injury risk, yet the required supplementation dosage for collegiate athletes is unclear. The objective of this study was to define the dosage of vitamin D3 supplementation required to beneficially affect serum 25-hydroxyvitamin D (25(OH)D) among a sample of collegiate basketball athletes. This was a quasi-experimental trial, participants were allocated to one of three groups of vitamin D3 daily at the beginning of pre-season training and dependent upon their baseline vitamin D status as follows: insufficient (<75 nmol/L) to 10,000 IU, sufficient (75–125 nmol/L) to 5000 IU and optimal (>125 nmol/L) to no supplementation. Follow-up assessments were completed ~ 5 months later in post season. The majority (n = 13) were allocated to 10,000 IU vs. n = 5 to 5000 IU and n = 2 to no supplementation. The 10,000 IU group showed the greatest change (35.0 ± 27.0 nmol/L) vs. the 5000 IU group (−9.3 ± 9.6 nmol/L) and no supplementation group (−41.6 ± 11.7 nmol/L, p < 0.01). Only 1 participant reached optimal status in the 10,000 IU group. In conclusion, a daily dosage of 10,000 IU vitamin D3 supplementation mitigated the high prevalence of vitamin D deficiency among collegiate basketball players but was insufficient for all to reach sufficient levels.